Atara Biotherapeutics Reports Q2 2026 Financial Results

What Happened

• On August 12, 2026, Atara Biotherapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release titled “Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress.” The company furnished that press release as Exhibit 99.1 to its Form 8‑K. The Form 8‑K was signed by Kevin G. Sarney, Interim Chief Financial Officer.

Key Details

• Filing date: August 12, 2026 (Form 8‑K Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026 (second quarter 2026).
• Exhibit included: 99.1 — press release with the financial results and operational update.
• Administrative exhibit: 104 — Cover Page Interactive Data File (Inline XBRL).

Why It Matters

• The 8‑K formally notifies investors that Atara has published its quarterly earnings and operational update; the press release (Exhibit 99.1) is the source for revenue, profit/loss, cash position, and any guidance or operational milestones. Investors should review the attached press release and any related investor materials or calls to see the specific financial figures and assess impacts on the company’s outlook and cash runway.